NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Immutep Limited (IMMP) Stock Analysis

Immutep Limited (IMMP) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

IMMP

$3.28

+$0.02 (+0.61%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IMMP with… →

IMMP Key Statistics

As of Oct 21, 2026
Trading
Open
$3.22
Previous Close
$3.26
Day's Range
3.21–3.40
52-Week Range
3.06–70.60
Volume
8.04K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.30
Valuation
Market Cap
$24.17M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.21
EPS (ttm)Profit attributable to each share over the last twelve months.
−7.30
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$42.72M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
7.37M
1-Year Return
+59.22%
Dividend and dates
Avg Volume
15.57K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, IMMP closed at $3.28, +59.22% over 1 year.

Immutep Limited (IMMP) has a market capitalization of $24.17M.

In fiscal 2024, IMMP reported revenue of $0.00.

IMMP Stock Return by Calendar Year

Immutep Limited (IMMP) 10-year return: what $10,000 became

1 year
$10,000 $15,922
+59.22%
5 years
$10,000 $7,523
−24.77%
10 years
$10,000 $11,182
+11.82%

If you had invested $10,000 in Immutep Limited (IMMP) 10 years ago, at the close on October 21, 2016, it would have been worth $11,182 at the close on October 21, 2026: +11.82% in total, +1.12% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+14.69%
2025+31.80%
2024−9.58%
2023+37.14%
2022−46.65%
2021+4.46%
2020+75.42%
2019−2.72%
2018+17.20%
2017−32.91%
2016 (partial year)−22.00%

As of October 21, 2026.

IMMP Revenue and Earnings by Fiscal Year

FY ends June
Fiscal yearRevenueNet incomeNet margin
2024$0.00−$42.72M—
2023$0.00−$39.90M—
2022$170.37K−$32.21M−18,906.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2024$0.00—−$46.56M−$42.72M—
2023$0.00—−$41.43M−$39.90M—
2022$170.37K—−$33.84M−$32.21M−18,906.5%

Annual figures as reported, in the company's reporting currency. As of June 30, 2024.

IMMP Valuation vs Biotechnology Median

Median of 608 stocks
MetricIMMPBiotechnology medianvs median
P/S ratio1.2113.300.1x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Immutep Limited (IMMP) is capitalised at $24.17M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector.

Over the past 52 weeks the price has ranged from $3.06 to $70.60. The most recent close on file for IMMP is $3.28, dated October 21, 2026. That is +$0.02 (+0.61%) against the previous close. The latest close sits 7.19% above that 52-week low.

Financial Health

In fiscal 2024, Immutep Limited reported revenue of $0.00. The same year closed with a net loss of $42.72M. Trailing earnings per share are −7.3.

Across the 3 fiscal years on file, revenue moves from $170.37K in 2022 to $0.00 in 2024. Of those 3 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 1.21. On price-to-sales that is 0.1 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Over the trailing twelve months the total return is +59.22%. Measured over 10 years, that is +1.12% a year compounded. Beta against the wider market is reported at 2.3. Daily returns over the trailing 10 years annualize to a volatility of 543.43%.

Growth & Income

The record shows no dividend for IMMP.

So far in 2026 the total return is +14.69%. Across the complete calendar years on file, 2020 returned +75.42% and 2022 returned −46.65%. Of the 9 complete calendar years on file, 5 finished higher.

Peer Comparison

Immutep Limited (IMMP) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Immutep Limited IMMP $24.17M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Immutep Limited has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Immutep Limited

Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer. Its product pipeline also includes AIPAC-003, which has completed an integrated Phase II/III clinical trial for the treatment of metastatic breast cancer; TACTI-003, which has completed a Phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (1L HNSCC); an investigator-initiated Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in patients with early-stage HR+/HER2-negative breast cancer; and EFTISARC-NEO, which is in a Phase II clinical trial for the treatment of soft tissue sarcoma. In addition, the company develops INSIGHT-003, which is in a Phase I trial for 1L non squamous non-small cell lung cancer (NSCLC); EOC 202, which has completed a Phase I trial for metastatic breast cancer; IMP761, an agonist LAG-3 antibody in a Phase I trial; IMP731, a LAG-3 depleting antibody that has completed a Phase II trial for ulcerative colitis and a Phase I trial for psoriasis; and ieramilimab/LAG525/IMP701, which are anti-LAG-3 antagonist antibodies. It has collaborations with Merck & Co., Inc., Institute of Clinical Cancer Research (IKF) at Krankenhaus Nordwest, the Maria Sklodowska-Curie National Research Institute of Oncology, EOC Pharma, Dr Reddy's Laboratories, Monash University, and George Washington University. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.

Visit website →